- $662.30m
- $251.53m
Olema Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary
Olema Pharma Q3 net loss widens on higher costs
Brief: Olema Pharmaceuticals Q3 Net Income USD -73.599 Million
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Olema Pharmaceuticals Q1 Net Income USD -53.089 Million
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Oncology drug developer Olema Pharmaceuticals' Q4 net loss widens on higher R&D costs
Brief: Olema Oncology Announces Departure Of Chief Operating And Financial Officer
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet
U.S. STOCKS ON THE MOVE-Constellation Energy, Williams-Sonoma
U.S. STOCKS ON THE MOVE-Lowe's, TJX Companies, Target
Olema Oncology dips after $190 mln equity offering following stock surge
Brief: Olema Oncology announces pricing of $190 million public offering of common stock
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology